Oppenheimer raised the firm’s price target on Pharming (PHAR) to $39 from $30 and keeps an Outperform rating on the shares following quarterly ...

Q4 2024 Management View CEO Fabrice Chouraqui highlighted a strong performance in 2024 with revenue growth of 21% to $297 million, exceeding guidance. He emphasized RUCONEST's growth of 11% to $252 ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Pharming Group (PHGUF) reports a 21% increase in full-year revenue, strategic Abliva acquisition, and positive financial outlook for 2025.

Dutch biopharma company Pharming (Euronext Amsterdam: PHARM) has reported a 21% increase in revenue for 2024, reaching $297 ...

(RTTNews) - Pharming Group N.V. (PHAR), a global biopharmaceutical company, on Thursday reported profit for the fourth quarter compared with loss last year. In the fourth quarter, net income came ...

Full Year 2024 Results Key Financial Results Revenue: US$297.2m (up 21% from FY 2023).

Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming's late-stage clinical pipeline, in line with our vision to become a leading global rare disease company Fabrice ...